Stand up to Cancer hails FDA approval of olaparib for advanced prostate cancer

(Stand Up To Cancer) Olaparib, recently FDA-approved for patients with an aggressive form of prostate cancer, is a precision therapy that targets certain molecular qualities of advanced prostate cancer in patients with genetic mutations including BRCA1/2 who progressed despite prior treatment. The SU2C-PCF Dream Team research first demonstrated>20% metastatic prostate cancer patients have mutations including BRCA1/2, and>10% of these are inherited, leading to their clinical trials that tested olaparib as a potential treatment for these patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news